ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife [Yahoo! Finance]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
The clearance for the NanoKnife System for prostate tissue ablation follows the completion of the pivotal PRESERVE clinical study and submission of results to the FDA in September. It is worthwhile to note that the PRESERVE clinical study assessed the safety and effectiveness of the NanoKnife System for ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). The latest regulatory clearance is a significant stepping stone for AngioDynamics to strengthen its foothold in the prostate tumor treatment space. Following the announcement on Dec. 9, shares of the company gained nearly 23.3% till yesterday's trading. Historically, the company has gained a high level of synergies from its various positive study outcomes and regulatory clearances. We expect market sentiment on the stock to continue to remain positive around this announcement, too. AngioDynamics currently has a market capitalization of $350.7 million. Its P/S ratio of 1.20 is lower than the ind
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor EventBusiness Wire
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- NanoKnife gains FDA clearance for prostate tissue ablation [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation [Yahoo! Finance]Yahoo! Finance
ANGO
Earnings
- 10/3/24 - Miss
ANGO
Sec Filings
- 12/4/24 - Form 4
- 12/4/24 - Form 3
- 11/15/24 - Form 8-K
- ANGO's page on the SEC website